USPTO's Patent Term View Oversteps Authority, Drug Co. Says
Drugmaker Exelixis Inc. has urged the Federal Circuit to overturn the patent office's current interpretation of the patent term adjustment statute, saying the office's take on the provision "oversteps" its authority...To view the full article, register now.
Already a subscriber? Click here to view full article